Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Direct acting antiviral treatment of chronic hepatitis C in Denmark : factors associated with and barriers to treatment initiation. / Sølund, Christina; Hallager, Sofie; Pedersen, Martin S; Fahnøe, Ulrik; Ernst, Anja; Krarup, Henrik B; Røge, Birgit T; Christensen, Peer B; Laursen, Alex L; Gerstoft, Jan; Bélard, Erika; Madsen, Lone G; Schønning, Kristian; Pedersen, Anders G; Bukh, Jens; Weis, Nina; DANHEP Group.
I: Scandinavian Journal of Gastroenterology, Bind 53, Nr. 7, 2018, s. 849-856.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Direct acting antiviral treatment of chronic hepatitis C in Denmark
T2 - factors associated with and barriers to treatment initiation
AU - Sølund, Christina
AU - Hallager, Sofie
AU - Pedersen, Martin S
AU - Fahnøe, Ulrik
AU - Ernst, Anja
AU - Krarup, Henrik B
AU - Røge, Birgit T
AU - Christensen, Peer B
AU - Laursen, Alex L
AU - Gerstoft, Jan
AU - Bélard, Erika
AU - Madsen, Lone G
AU - Schønning, Kristian
AU - Pedersen, Anders G
AU - Bukh, Jens
AU - Weis, Nina
AU - DANHEP Group
PY - 2018
Y1 - 2018
N2 - OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.
AB - OBJECTIVES: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.MATERIALS AND METHODS: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.RESULTS: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38-3.28), previous treatment failure OR 2.58 (CI: 1.84-3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18-2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59-12.91).CONCLUSIONS: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.
U2 - 10.1080/00365521.2018.1467963
DO - 10.1080/00365521.2018.1467963
M3 - Journal article
C2 - 29720023
VL - 53
SP - 849
EP - 856
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 7
ER -
ID: 196714444